Quality Risk Management for Quality system

质量风险评估在质量保证体系中的应用

辉瑞制药有限公司 解馨







The 10 step approach to QRM



Case Studies



Final Points

QRM - What is it?	er,
Structured approach to understanding and managing risk in the Pharmaceutical Industry	
Started from ICHQ9 "Quality Risk Management" working group	
Becoming more of a regulatory expectation	
FDA guideline in June 2006	
EU added to the EMEA website in January 2006	
Japan adopted in Sept 2006	
Chinese GMP 2011Edition, effective March 1	

QRM – Why do it?

Regulatory and Compliance

- Becoming more and more a regulatory expectation
- Patients and Customers
 - Greater assurance of patient safety
 - Elements of risk a more visible
 - Risk reduction actions can be better identified and linked to each risk
- Business Case:
 - Makes decisions more robust
 - Prioritise/focus resources
 - Eliminate un-required activities and thus reduce workload
 - Support lean/agile endeavours/projects
 - Support our continuous improvement



QRM and other Methodologies

- Quality Risk Management may be new, but we are already using some of the thinking in the way our systems and processes are set up
- There is also a lot of other methodologies or approaches that are in place in Pfizer
- It's important to understand the differences and similarities between QRM and:
 - Root Cause Analysis
 - Commissioning and Qualification
 - Operational Excellence (eg. Six Sigma Green Belt Projects)



Overview - Principles

Two primary principles of QRM:

- The evaluation of the risk to quality should be based on scientific knowledge and ultimately link to the protection of the patient
- The level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk



Overview – Process





The 10 step approach to QRM

- 1. Collect and organise information
- 2. Define the risk question
- 3. Choose tool
- 4. Determine risk factors
- 5. Define the scales for risk components
- 6. Define matrix
- 7. Determine the threshold for action
- 8. Apply the tool
- 9. Define risk reducing measures
- 10. Document and Approve

plus Ongoing Risk Review





Phzer

Step 1 – Collect and Organise information

- Gather relevant information and references
 - PQSs, Regulations, Data, etc.
- Identify any background or preliminary information
- Agree on assumptions
- Tools which can be used to organize available information
 - Brainstorming
 - Flow Charting
 - Process Mapping



Step 2 – Define Risk Question

- Clearly defining the initial risk question or issue is essential for an effective QRM outcome.
- Clearly defining the risk question helps to:
 - Focus on the objective
 - Clarifies the scope
 - > Assure resources are effectively applied
 - Provides context



Step 3 – Choose Tool

- There is no wrong tool
- Simple tools are valuable
- Various methods of analysis are largely interchangeable
- Methods/tools can be modified to meet needs
- Available information and the risk question will drive selection of tools





Step 3 – Choose Tool (Summary)

ΤοοΙ	Includes	Scales	Scale Items	Threshold
RRF - Risk Ranking and Filtering	SxP	Words (only L,M,H)	Not defined	Use standard matrix. Action taken when High outcome. (Medium to be considered)
PHA - Preliminary Hazard Analysis	SxP	Words (L,M,H or other)	Each scale item defined	Prepare matrix and define action requirements
<i>FMEA -</i> Failure Mode and Effect Analysis	SxPx D	Numbers	Each scale item defined	Define action requirements by RPN



Step 4 – Determine Risk Factors

Severity

- What are the factors which must be considered that will have an impact on the patient / compliance / company (consequences)?
 - Probably covered in your risk question

Probability

What is the likelihood that the impact on the patient/compliance/company will occur?

Detection

- Can you detect the risk?
- > Remember low detection \rightarrow high risk



Step 5 – Define Scales

Use of different scales:

- High, Medium, Low
- Severe, Major, Minor, Negligible
- Linear: 1, 2, 3, 4
- Exponential: 1, 2, 4, 8
- Logarithmic: 1, 10, 100, 1000
- Self made: 1, 3, 7, 10



Step 5 – Define Scales (cont.)

Severity Term	Description & Definition	Probability (Frequency)	Description & Definition
Severe	Potential death or permanent injury	Frequent	Continual occurrences
Major	Potential serious injury, but not permanent	Probable	Occurrences are frequent probable reoccurrence
Minor	Potential minor injury, but not permanent	Occasional	Isolated occurrences
Negligible	Potential minor discomfort, but not permanent	Remote	Isolated occurrences possible; Don't expect reoccurrence



Step 6 – Define Matrix

Example RRF – Matrix



Increasing Severity



Step 6 – Define Matrix (cont.)



Example PHA – Matrix

Frequency /	<u>Severity</u>				
<u>Probability</u>	Negligible	Minor	Major	Severe	
Frequent	Low Risk	Intermediate Risk	High Risk	High Risk	
Probable	Low Risk	Intermediate Risk	High Risk	High Risk	
Occasional	Trivial Risk	Intermediate Risk	Intermediate Risk	High Risk	
Remote	Trivial Risk	Low Risk	Intermediate Risk	Intermediate Risk	



Step 7 – Determine Threshold for Action

Action thresholds:

- High Risk must be reduced
- Intermediate Reduce risk to As Low as Medium Reasonably Possible (ALARP)
- Low Reduce risk to ALARP, considering cost/benefit
- Trivial Generally acceptable level of risk



Step 8 – Apply Tool

- List the potential risk items
- Organise by risk category (Consumer/Patient, Compliance, Business/Producer)
- Example for a batch/product deviation:
 - Consumer /Patient
 - Is it a product efficacy issue?
 - Is it a product strength issue?
 - Is it a medically necessary supply issue?
 - Compliance
 - Did we breach GMP?
- Example for a decision to remove/discontinue a certain test:
 - Consumer/Patient
 - Could we have an an issue with product identity?
 - Compliance
 - Is this test registered?



Step 8 – Apply tool (cont.)



Potential Risk	Probability	Severity	Outcome
Consumer Risk A	Low	Med	Low
Consumer Risk B	Med	Med	Med
Compliance Risk A	High	Med	High
Producer Risk A	Low	High	Med

Note: Table will be different for PHA and FMEA.



Step 9 – Define Risk Reduction Measures

Two basic risk control strategies:

- Prevent
 - Stop the hazard occurring at all
- Protect
 - Decrease the severity/impact
 - E.g. If severity unknown, get a medical opinion
 - E.g. Installing an eye-wash station
 - Decrease the probability
 - E.g. Slow down the machine rate
 - E.g. Perform maintenance less frequently
 - Increase the detection
 - E.g. Perform 100% visual inspection
 - E.g. Implement additional routine checking



Step 9 – Define Risk Reducing Measures

- Once measures have been implemented, reapply tool to show:
 - How each individual potential risk was reduced
 - > What the overall level of risk is
- Shows that we have:
 - Followed the QRM process
 - Understood and accepted the residual risk
 - Effectively completed the analysis



Step 10 – Document and Approve

Risk Question:

Assessment

Team:

Potential Harm	Risk An	alysis	Risk Evaluation	Recommended action	Responsible party and target date	Risk An	alysis	Risk Evaluation
	Probability (P ₁)	Severity (S ₁)	Initial Score (P ₁ x S ₁)			Probability (P ₂)	Severity (S ₂)	Final Score (P ₂ x S ₂)

Prepared By:	Date
Business Unit Approval:	Date
QA Approval:	Date



Ongoing Risk Review

At Pfizer

SQRT/AQRT

- Site Validation Committee
- Corporate Auditors

Outside Pfizer

- Inspectors
- Regulatory Authorities



QRM – What can we do with QRM?

Retro-actively:

- Making decisions around product and quality risk for deviations/issues/complaints
- Pro-actively:

>

- Qualification & Validation
- Change Management Impact assessments
- PM Programs and Calibration
- > Audit Frequencies
- Materials Management
- Training Optimisation









Slide 27

1. Collect and organise information

What are the different types of suppliers used by the site? What do we know about each supplier?

2. Define the risk question

What is the supplier audit schedule that will ensure that suppliers presenting a high risk to the patient are audited in a more frequent manner?



3. Choose Tool – FMEA

4. Define the meaning of risk components

> Severity

- Type of products
- Number and significance of quality defects

Probability

- Complexity of the site (multi products)
- Detection
 - Robustness of the quality system
 - Audit history



5. Scale for Severity

Factor	Definition	Example
10	Sterile products or recall of product	Sterile products, sterile APIs, sterile packaging material
6	Product orally administered or product rejected	Tablets, capsules, primary packaging material
3	Topical products and compounds not directly used by patient or backlog of release of lots due to deviations	Creams, ointments, non- sterile API's, secondary pre- printed packaging
1	Compounds used during manufacturing process	Starting materials, raw material, excipients



5. Scale for Probability

Factor	Definition	Example
8	Highly complex structure of the site	Multi products including products to be produced under strict separation schemes
4	Complex structure of the site	Multi products
1	Dedicated site	One product



5. Scale for Detection

Factor	Definition	Example
8	Compliance status is unknown or defects in the Quality Systems are definitely not known	Never audited, last audit more than five years ago, result of last audit had critical observations
4	Compliance status could be affected by time or changes or defects in Quality System might not be known	Last audit three to four years ago, change in site owner, global reorganisation, results of audit had major observations
2	Compliance status has good reputation or defects in the Quality System might be possible	Last audit two/three years ago, result of last audit resulted in minor observations
1	Compliance status has been recently assessed or defects in the Quality System has been assessed	Last audit was up to 2 yeas ago, satisfactory audit results (comments)



6. Define Matrix

7. and Threshold

When RPN is at least 96 (6S x 4P x 4D) = schedule audit

8. Apply the tool

Supplier	Severity Score (S)	Probability Score (P)	Detectability Score (D)	Total Risk Score (SxPxD)
Supplier A				
Supplier B				
Supplier C				
Supplier D				



9. Define risk reducing measures

Supplier	Total Risk Score (SxPxD)	Recommended action and target date
Supplier A		Audit on month, year
Supplier B		
Supplier C		
Supplier D		

10. Document and Approve

SQRT to approve QRM and Audit Schedule



Last comments on audit scheduling:

- Use of a risk based audit scheduling will make the fixed frequency approach obsolete
- A rolling schedule that can be adapted if new information becomes available, *e.g.* recall situation can raise the priority of the audit
- This tool does not define the focus areas within each audit
- Additional risk factors, applicable to individual suppliers, can also be considered. *e.g.* availability / relationship with the supplier



Step 1 – Collect and Organise Information

- Sites employ a default frequency for periodic review of SOPs.
- There are no regulations specifying a required review period for SOPs,
- Clear expectation that SOPs are current.

Step 2 – Define the Risk Question

What is the optimal frequency of periodic review, for all SOPs, that ensures that product quality and regulatory compliance is maintained?

Step 3 – Choose tool

- Risk Ranking and Filtering
- Simple but sufficient for this analysis.

Step 4 – Determine Risk Factors

- Probability what is the likelihood of having non-compliant or deficient procedures which have the potential to impact product quality or regulatory compliance attributed to lack of timely document review that could remain unchecked or undetected?
- Severity what is the impact on product quality and regulatory inspection outcomes from having an SOP in a non-compliant (out of currency) status?

Step 5 – Define the Scales

- Probability low, medium, high
- Severity low, medium, high

Step 6 – Define the Matrix

easing Probability		High	Medium	High	High
		Medium	Low	Medium	High
		Low	Low	Low	Medium
Incr			Low	Medium	High

Increasing Impact

Step 7 – Determine the Threshold for Action

- Low Periodic Review of 5 years
- Medium Periodic Review of 2- 3 years
- High Periodic Review of 1 year

Step 8 – Apply the Tool

Categorize SOPs

SOP Category	Subject	Sub-group	Probability	Outcome	score
1.Plant	1.Safety		low	low	low
	2.Plant Process	cess Labels management		high	medium
		Project Management	low	high	medium
	3.Plant Cleaning		low	medium	low
	4. Plant Equipment		low	medium	low
	5.Plant Training / Administration	Documentation	low	medium	low
		Training	low	medium	low
	Validation (System, Cleaning & Process)		medium	high	high
	Security 1		low	low	low
Compliance		low	high	medium	
	RFT		medium	medium	medium
		Change Control	medium	high	high
		Health	low	low	low

SOP Category	Subject	Sub-group	Probability	Outcome	score
2.Quality Operat ion	1.QO Safety		low	low	low
	2.Q0 Process Sampling, Testing and Release		low	high	medium
		IPC	low	high	medium
		Investigation	medium	high	high
		Analytical Method Validation	low	high	medium
		GLP	low	high	medium
	3.QO Cleaning	low	medium	low	
	4.QO Equipment		low	medium	low
	5.QO Training / Administration	Quality Assurance	medium	high	high
		Quality Control	low	high	medium
		Documentation	low	medium	low
		Training	low	medium	low

Case 2 Using QRM to determine SOP review date *pfcer* Step 9 – Define Risk Reducing measures Determine appropriate review period for each SOP based on QRM

PLANT TRAIING/ADMINISTRATION

Management Of Plant Procedure	2 Y
Plant Training System	3 Y
Correct Documentation.	3 Y
Management of Batch Documents	2 Y
Process Validation Protocols	1 Y
Revalidation Policy	1 Y
The General Visit PPL Procedure	5 Y
GMP Training Procedure	2 Y
Procedure of Using the out-permission ticket	5 Y
Visitor Reception and Traffic Managerment	5 Y
Handling Procedure of Security Incidents	5 Y
Plant Security Patrolling Procedure	5 Y
Security Guard's Working Regulations	5 Y
Manipulate procedure of security alarm and monitor system	5 Y

Slide 47

Step 10 – Document and Approve

- Change control request.
- Implement these review periods.
- SOP review system to ensure that this SOP review occurs within 3 months of the specified requirement.



Case 3 Change control system with QRM Pfizer Change Control is an important element in pharmaceutical quality system. Establishment of

pharmaceutical quality system. Establishment of effective change control process is key to ensure continuous improvement and manufacture of quality products.

China GMP Edition 2011

There should be change control system established in plant, to evaluate and manage all changes impacted on product quality.





Step 1 information collection

- A solid dosage API will change manufacturing location from Site A to Site B. The process in the two sites are both three-step method except for one-step reaction path, an original material as well as a little difference of the solvent system. 3 respective batches of new and old API comparative test by current specification shows: Chemical property matches. Physical property also matches except for particle size distribution difference. The initial dissolution rate data shows particle difference impacts dissolution.
- The location change impacts single market registration. The EIR (Establishment Inspection Report) from FDA is required by the target market.

Step 2 Identify Risk question

What is the quality and regulatory risk caused to the solid dosage by API manufacturing location change? What action should be taken?



Step 3 tools selection

RRF (Risk Ranking & Filtering)

Step 4 Determine Risk Factors

Severity :

Quality risk to product caused by the product quality property's incompliance with the accepted specification.

Regulatory risk caused by the change over the limitation of register and GMP .

Possibility :

The possibility of the product quality property's incompliance with the accepted specification

The possibility of the change over the limitation of register and GMP



Severity – low, medium, high

Step 6 – Define the Matrix

easing Probability		High	Medium	High	High
		Medium	Low	Medium	High
		Low	Low	Low	Medium
Incr			Low	Medium	High

Increasing Impact

Step 7 – Determine the Threshold

- Low Risk could be accept no further action needed
- Medium Risk could be recued if possible
- High Risk must be reduced

Step 8 Apply the tools

	Ri	Risk Evaluation	
Quality Risk	ality Risk Possibility(P)		Risk Score (P x S)
Quality Risk			
Specification(Impurity, Residual Solvent, Particle Size Distribution)	High	High	High
Test Method Applicability	High	High	High
Dissolution Rate	High	High	High
Process Validation	High	High	High
Stability	High	High	High
Compliance Risk			
Registration	High	High	High
GMP(EIR)	Low	High	Medium

Slide 60

Step 9 Define risk reducing measures

	Rank Ac		Responsible Party and Target Date
Quality			
Specification(Impurity, Residual Solvent, Particle Size Distribution)	High	1. Improve process: Investigation demonstrates drying process variation is the cause of particle size difference. New API site is required to optimize drying process parameter to make the particle size distribution reaching the current specification.	2007.12
		2. Set up new specification: Update impurity, residual solvent control specification to adapt to the new process.	
		3.Complete 3 batches test result comparison.	
Test Method Applicability	High	Evaluate the applicability of the method	2008.5
Dissolution Rate	High	Complete Dissolution comparative test.	2008.5
Process Validation	High	Complete 3 batches process validation	2008.5
Stability	High	Carry out accelerated and ongoing stability study	2008.8
Compliance			
Registration	High	Complete Registration	2009.3
GMP(EIR)	Medium	Provide EIR	2008.8

Slide 61

Step 9 Apply tools again

	Risk Evaluation	Risk A	Analysis	Risk Evaluation
	Initial Score	Р	S	Final Score
Quality Risk				
Specification(Impurity, Residual Solvent, ,Particle Size Distribution)	High	Low	Low	Low
Test Method Applicability	High	Low	Low	Low
Dissolution Rate	High	Low	Low	Low
Process Validation	High	Low	Low	Low
Stability	High	Low	Low	Low
Compliance Risk				
Registration	High	Low	Low	Low
GMP(EIR)	Medium	Low	Low	Low

Step 10 – Document and Approve

Potential Harm	Risk Analysis		Risk Evaluation	Processing and Anti-	Responsible	Risk Analysis		Risk Analysis
Fotential Harm	Possibility	Severity	Initial Score	Recommended Action	Target Date	Possibility	Severity	Final Score
	(P1)	(S1)	(P1 x S1)			(P2)	(\$2)	(P2 x S2)
Quality Risk								
Specification(Impurity, Residual Solvent, ,Particle Size Distribution)	High	High	High	1.Improve process:Particle size Reaches specification 2.Set up new specification 3.Compare 3 batches test	2007.12	Low	Low	Low
Test Method	High	High	High	Evaluate Method	2008.5	Low	Low	Low
Dissolution Rate	High	High	High	Dissolution Rate Test	2008.5	Low	Low	Low
Process Validation	High	High	High	3 batches process validation	2008.5	Low	Low	Low
Stability	High	High	High	Accelerated long-term stability study	2008.8	Low	Low	Low
Compliance Risk								
Registration	High	High	High	Complete Registration	2009.3	Low	Low	Low
GMP EIR	Low	High	Medium	Provide EIR	2008.8	Low	Low	Low

- Change Control is an important element in pharmaceutical quality system.
- Establishment of effective change control process is key to ensure continuous improvement and manufacture of quality products.
- Design and optimization of pharmaceutical products change control process based on quality risk management concept.

Final Points

Tips to successfully embed QRM:

- Have leadership support /accountability for QRM
- Need all functions involved not only Quality
- Provide clear guidance to your colleagues on where and how QRM should be used
 - Incorporate philosophy into existing SOPs
 - Provide training in tools and methodology
- Identify site QRM Champions
 - Across all functions/departments, not just Quality
- Have a proactive approach to finding opportunities to use QRM
- Communicate QRM analysis and outcomes
- "Listen" to your QRM analysis
 - Take active decisions and actions



Dizer





Thank you

Slide 67